Associations between remnant lipoprotein cholesterol and central systolic blood pressure in a Chinese community-based population: a cross-sectional study

Kaiyin Li¹, Fangfang Fan¹, Bo Zheng¹, Jia Jia¹, Bo Liu¹, Jiahui Liu¹, Chuyun Chen¹, Jing Zhou¹⁺⁺, Yan Zhang¹²⁺⁺ and Yong Huo¹

Abstract

Background: The lipid profile is reportedly related to peripheral blood pressure or pulse wave velocity. However, no studies have investigated the associations between lipid parameters, especially remnant lipoprotein cholesterol (RLP-C), and central systolic blood pressure (cSBP).

Methods: This study used baseline data of a community-based cohort in Beijing, China. Participants who had been treated with anti-hypertensive or lipid-lowering agents were excluded. RLP-C is equal to total cholesterol (TC) minus the sum of low-density lipoprotein cholesterol (LDL-C) and high-density lipoprotein cholesterol (HDL-C). An Omron HEM-9000AI device was used to measure non-invasive cSBP. The associations between blood lipid profile and non-invasive cSBP were evaluated using multivariable regression models.

Results: The 5173 included participants were 55.0 ± 8.5 years old; 35.7% (1845) of participants were men. Increased cSBP was significantly associated with increased TC, LDL-C, non-high-density lipoprotein cholesterol (non-HDL-C), triglyceride (TG), and RLP-C but with decreased HDL-C, even after adjusting for possible covariates. When simultaneously entering individual pairs of RLP-C and other blood lipid parameters into the multivariable regression model, RLP-C remained significantly associated with cSBP, even after adjusting for other lipids. Compared with participants who had RLP-C levels in the first quartile (Q1), cSBP for those with RLP-C in Q4 was increased to 4.57 (95% confidence interval [CI]: 3.08–6.06) mmHg after adjusting for LDL-C, 4.50 (95%CI: 2.98–6.02) mmHg after adjusting for TC, 3.91 (95%CI: 1.92–5.89) mmHg after adjusting for TG, 5.15 (95%CI: 3.67–6.63) mmHg after adjusting for HDL-C, and 4.10 (95%CI: 2.36–5.84) mmHg after adjusting for non-HDL-C.

Conclusions: Increased blood RLP-C level was significantly associated with higher cSBP in a Chinese population, independently of other lipids, which indicates its importance in individual cardiovascular risk assessment.

Keywords: Lipids, Remnant lipoprotein cholesterol, Non-high-density lipoprotein cholesterol, Triglyceride, Cholesterol, Low-density lipoprotein cholesterol, Non-invasive central systolic blood pressure, Arterial stiffness
Background
Hypertension accounts for the largest proportion of the global disease burden and mortality in recent years [1]. In 2019, elevated systolic blood pressure (SBP) led to approximately 10.8 million deaths and the highest percentage of disability-adjusted life-years [2]. Hypertension is currently defined according to the peripheral blood pressure; however, pulse wave analysis (PWA) has enabled reproducible and non-invasive measurement of central hemodynamics. Numerous clinical studies have indicated that non-invasive central systolic blood pressure (cSBP) measurement may improve risk stratification for cardiovascular diseases owing to its stronger association with hypertension-mediated organ damage [3–7].

Previous studies have identified an association between blood lipids and blood pressure, although most such studies have focused on the relationships between hypercholesterolemia or hypertriglyceridemia and peripheral blood pressure [8–11]. Additionally, patients with increased remnant lipoprotein cholesterol (RLP-C) levels are more likely to develop incident cardiovascular diseases [12–14]. A 10-year longitudinal study in Japan showed associations between higher plasma RLP-C and incident hypertension [15]. To the best of our knowledge, the relationship between RLP-C and central blood pressure remains unknown. Hence, this retrospective study was conducted to investigate the associations between non-invasive cSBP and lipid profile levels, especially RLP-C.

Methods
Study design
This retrospective study used baseline data of a Beijing community-based cohort in China [16]. Among the initial 9540 participants recruited via phone calls or recruitment posters between December 2011 and April 2012, 8062 participants (84.5%) had effective data of cSBP and RLP-C at baseline. Those participants treated with anti-hypertensive agents (n = 2630) and/or lipid-lowering agents (n = 952) were excluded owing to therapeutic effects on cSBP and blood lipids of these drugs. Finally, 5173 eligible participants were included in the analysis.

Data collection
Trained research staff collected data by standards, including information on lifestyle, history of diseases and medications, and physical examination. Smoking status, drinking status, hypertension, and diabetes mellitus (DM) have been defined previously [17]. Calculations of estimated glomerular filtration rate (eGFR) and body mass index (BMI) were according to those in a previous publication [18]. After an overnight fast, blood samples were obtained from each participant via forearm venipuncture. Serum glucose, lipid, and creatinine levels were tested using previously published methods [19]. Non-high-density lipoprotein cholesterol (non-HDL-C) was calculated as subtraction of the high-density lipoprotein cholesterol (HDL-C) from the total cholesterol (TC), while the RLP-C was defined as TC minus the sum of low-density lipoprotein cholesterol (LDL-C) and HDL-C.

Before central blood pressure measurement, all participants were required to sit quietly for 5 min. Non-invasive cSBP was measured using the validated HEM-9000AI device (Omron Healthcare, Kyoto, Japan) [20–24]. Each participant underwent simultaneous measurement of left radial applanation tonometry and right brachial cuff oscillometric pressure. Radial waveforms were analyzed to obtain the peripheral systolic pressure peaks, and were then calibrated using the measured brachial blood pressure. A linear regression model with the late peak of the peripheral systolic pressure was used to calculate the non-invasive cSBP. This measurement was not repeated due to the tight research schedule.

Statistical analysis
Mean ± standard deviation was used to describe continuous variables with a normal distribution, and differences were determined with one-way analysis of variance. Median (interquartile range) was used to describe non-normally distributed variables, and differences were determined using the Kruskal-Wallis rank test. Number (%) was used to describe dichotomous variables, and differences were determined using the chi-square test.

Relationships between lipid parameters and cSBP level were examined with generalized additive models using a spline smoothing function. Associations between cSBP and different blood lipid parameters (as continuous variables and quartiles [Q]) were investigated using univariable and multivariable regression models. Age, sex, BMI, eGFR, smoking and drinking status, DM, antidiabetic drug use, myocardial infarction and stroke history were adjusted in multivariable regression analyses. Furthermore, independent associations of RLP-C with cSBP, adjusted for other lipid parameters, were determined by simultaneously entering the pairs of RLP-C and other lipid parameters into the multivariable regression models one at a time. With regard to possible collinearity, the variance inflation factor (VIF) was calculated for the included variables in each multivariable regression model.

Empower(R) (www.empowerstats.com, X&Y Solutions, Inc., Boston, MA, USA) and R (http://www.R-project.org) were used for data analyses, and two-sided P values < 0.05 were regarded as statistically significant.
Results
Baseline characteristics of enrolled participants
Table 1 summarizes the characteristics of enrolled participants according to quartiles of RLP-C. The 5173 included participants were 55.0 ± 8.5 years old, and 35.7% (1845) were men. Participants with a higher RLP-C level had increased levels of TC, triglyceride (TG), LDL-C, and non-HDL-C, as well as cSBP ($P < 0.001$). Despite no intergroup difference in the percentage of myocardial infarction or stroke history, participants with a higher RLP-C level tended to be older, male, more likely to smoke and drink, and to have higher BMI, worse renal function, a higher ratio of DM, hypertension ($P < 0.001$) and antidiabetic medication use ($P = 0.013$).

Associations of RLP-C and other lipid profiles with cSBP, considered individually
The smoothing curves of cSBP by lipid parameter after adjusting for possible covariates are shown in Fig. 1. The smoothing curves showed a positive linear association between most lipid parameters and cSBP, except that a negative linear association with the HDL-C level and a non-linear trend with RLP-C level were observed.

Associations between the blood lipid profile and cSBP are summarized in Table 2. In the univariable analyses, cSBP showed a graded positive relationship with RLP-C, TC, TG, LDL-C, and non-HDL-C levels, but a graded negative relationship with the HDL-C level ($P < 0.001$). In the adjusted multivariable analyses, higher cSBP was significantly associated with increases in TC, TG, LDL-C, RLP-C, and non-HDL-C levels but decreased HDL-C level.

Associations of RLP-C and other lipid profiles with cSBP, considered simultaneously
The VIF calculated for the included variables in each multivariable regression model did not show any collinearity (Supplementary materials). Table 3 shows the relationship of RLP-C level and other blood lipid parameters with non-invasive cSBP, with simultaneous entry of RLP-C and other lipid in pairs into the multivariable regression models, after adjusting for covariates. Compared with participants who had RLP-C in Q1, the cSBP for those with RLP-C in Q4 was increased to 4.57 (95% confidence interval [CI]: 3.08–6.06) mmHg after adjusting for LDL-C, 4.50 (95%CI: 2.98–6.02) mmHg after

Table 1 Baseline characteristics of all participants by RLP-C quartile

| Variables                  | Total   | RLP-C, mmol/L |        |        |        | P Value |
|----------------------------|---------|---------------|--------|--------|--------|---------|
|                            |         | Q1 (< 0.39)   | Q2 (0.39–< 0.54) | Q3 (0.54–< 0.73) | Q4 (≥ 0.73) |        |
| n                          | 5173    | 1269          | 1283   | 1318   | 1303   | < 0.001 |
| Age, y                     | 55.0 ± 8.5 | 54.2 ± 8.8 | 55.3 ± 9.1 | 55.5 ± 8.2 | 55.0 ± 7.9 | < 0.001 |
| Male, n (%)                | 1845 (35.7%) | 365 (28.8%) | 444 (34.6%) | 476 (36.1%) | 560 (43.0%) | < 0.001 |
| BMI, kg/m²                 | 25.5 ± 3.3 | 24.0 ± 3.0 | 25.3 ± 3.2 | 26.1 ± 3.2 | 26.7 ± 3.1 | < 0.001 |
| eGFR, mL/min·1.73m²        | 96.8 ± 12.0 | 98.7 ± 11.4 | 96.9 ± 11.9 | 96.1 ± 11.9 | 95.4 ± 12.5 | < 0.001 |
| cSBP, mmHg                 | 129.7 ± 17.3 | 126.1 ± 16.8 | 129.0 ± 17.3 | 130.2 ± 16.8 | 133.2 ± 17.4 | < 0.001 |
| TC, mmol/L                 | 5.4 ± 1.0 | 4.8 ± 0.8 | 5.1 ± 0.8 | 5.5 ± 0.9 | 6.0 ± 1.1 | < 0.001 |
| TG, mmol/L                 | 1.2 (0.9–1.8) | 0.8 (0.6–0.9) | 1.1 (0.9–1.3) | 1.4 (1.2–1.7) | 2.3 (1.8–3.1) | < 0.001 |
| HDL-C, mmol/L              | 1.5 ± 0.4 | 1.8 ± 0.4 | 1.5 ± 0.3 | 1.4 ± 0.3 | 1.2 ± 0.3 | < 0.001 |
| LDL-C, mmol/L              | 3.3 ± 0.8 | 2.7 ± 0.6 | 3.2 ± 0.6 | 3.5 ± 0.7 | 3.7 ± 1.0 | < 0.001 |
| RLP-C, mmol/L              | 0.5 (0.4–0.7) | 0.3 (0.2–0.4) | 0.5 (0.4–0.5) | 0.6 (0.6–0.7) | 0.9 (0.8–1.1) | < 0.001 |
| Non-HDL-C, mmol/L          | 3.9 ± 1.0 | 3.0 ± 0.6 | 3.6 ± 0.6 | 4.1 ± 0.7 | 4.8 ± 1.0 | < 0.001 |
| Smoking, n (%)             | 1038 (20.1%) | 163 (12.8%) | 219 (17.1%) | 275 (20.9%) | 381 (29.2%) | < 0.001 |
| Drinking, n (%)            | 1255 (24.3%) | 250 (19.7%) | 299 (23.3%) | 317 (24.1%) | 389 (29.9%) | < 0.001 |
| Prevalence of cardiovascular disease, n (%) | | | | | | |
| Diabetes mellitus          | 953 (18.4%) | 159 (12.5%) | 208 (16.2%) | 253 (19.2%) | 333 (25.6%) | < 0.001 |
| Self-reported Myocardial Infarction | 21 (0.4%) | 0 (0.0%) | 7 (0.6%) | 7 (0.5%) | 7 (0.5%) | 0.077 |
| Self-reported Stroke history | 97 (1.9%) | 21 (1.7%) | 30 (2.3%) | 28 (2.1%) | 18 (1.4%) | 0.261 |
| Hypertension               | 1342 (25.9%) | 237 (18.7%) | 311 (24.2%) | 355 (26.9%) | 439 (33.7%) | < 0.001 |
| Antidiabetic medication use | 325 (6.3%) | 60 (4.7%) | 76 (5.9%) | 88 (6.7%) | 101 (7.8%) | 0.013 |

Data are presented as mean ± standard deviation for normally distributed continuous variables, median (interquartile range) for non-normally distributed continuous variables, and number (percentage) for dichotomous variables.

Abbreviations: BMI body mass index, eGFR estimated glomerular filtration rate, cSBP central systolic blood pressure, TC total cholesterol, TG triglyceride, HDL-C high-density lipoprotein cholesterol, LDL-C low-density lipoprotein cholesterol, RLP-C remnant lipoprotein cholesterol, non-HDL-C non-high-density lipoprotein cholesterol.
Fig. 1 (See legend on next page.)
adjusted for TC, 3.91 (95% CI: 1.92–5.89) mmHg after adjusting for TG, 5.15 (95% CI: 3.67–6.63) mmHg after adjusting for HDL-C, and 4.10 (95% CI: 2.36–5.84) mmHg after adjusting for non-HDL-C. The other lipid parameters were not significantly associated with cSBP after adjusting for RLP-C.

Discussion

The present study shows associations between cSBP and blood lipid profiles, especially RLP-C, in a community-dwelling Chinese population. In further analyses by simultaneously entering RLP-C level and other lipid parameters in pairs, the RLP-C level showed a stronger association with non-invasive cSBP.

Although different physiological indices, blood pressure and lipid profiles have overlapping processes owing to common cardiovascular risk factors and complications. Both hypertriglyceridemia and hypercholesterolemia are associated with higher peripheral blood pressure, as reported in previous cross-sectional studies [8–11]. A cohort study further showed that adolescents with a higher TG to HDL-C ratio had a higher risk of developing adult hypertension in a 20-year follow-up [25]; similar results were also observed in another prospective cohort study among pregnant women [26]. Mechanisms such as endothelial cell dysfunction, neuroendocrine system activation, increased salt sensitivity and reduced sodium clearance by nephrons, and higher L-type calcium channel activities in the smooth myofibrils contributed to the relationship [9, 27–33]. However, previous studies focused on peripheral blood pressure, although central blood pressure has been more strongly associated with cardiovascular outcome and hypertension-mediated organ damage [3–7].

Arterial stiffness can be evaluated non-invasively using two-dimensional imaging techniques, pulse wave velocity (PWV), cardio-ankle vascular index (CAVI), and PWA, although carotid-femoral PWV is currently more reliable [34–36]. Associations between TG levels and arterial stiffness have been reported, using all measurements of the CAVI [37], brachial-ankle PWV [38], and carotid-femoral PWV [39]. Regarding cholesterol, aortic stiffness has been positively associated with TC, LDL-C, and non-HDL-C levels, and negatively associated with HDL-C level [8, 40–42]. Moreover, large artery stiffness and blood pressure control are improved with statin therapy in patients with hypertension [43], independently of changes in the LDL-C level [44]. The findings of the present cross-sectional study suggested that the blood lipid profile is associated with non-invasive cSBP, and this association might be explained by vascular impairment. Compared with PWV, central blood pressure is more than a tool to measure aortic stiffness; it is associated with a more complex set of determinants, including the physical properties of systemic arteries, PWV, the travel time of a forward wave and its reflection, and the distance to the major reflecting site of a pulse wave [45]. Relationships of these determinants and lipids have been discussed previously. Another cross-sectional study used PWA to show associations between the LDL-C level and wave reflection [46]. Hence, cSBP and PWV are both associated with the lipid profile owing to their shared determinant of aortic stiffness, whereas other determinants of cSBP may enhance this association.

Notably, RLP-C was more strongly associated with cSBP than the other lipid parameters analyzed in the present study, possibly because of its physiological characteristics. RLP-C is defined as the cholesterol content in TG-rich lipoproteins (TRLs), namely intermediate-density lipoprotein (IDL), very low-density lipoprotein (VLDL), and chylomicron remnants [47–49]. As TG contents are gradually degraded by lipoprotein lipase in the bloodstream, the cholesterol in RLP-C could also be involved in atherosclerosis plaque formation and subsequent cardiovascular events, and it has been recognized as more atherogenic and proinflammatory than the cholesterol in LDL-C [48–52]. A recent study indicated associations of plasma TGs and relatively small-sized LDL particles with the carotid-femoral PWV, despite no significant associations between VLDL/large IDL subclasses (the main carriers of TG in the blood) and the carotid-femoral PWV [53]. This raises the possibility that the TG content in TRLs may indirectly influence this process, considering greater small dense LDL generation in the presence of high VLDL-TG levels [54]. Another study conducted in Japan also linked higher serum RLP-C levels with increased intima-media thickness-defined carotid atherosclerosis and CAVI-defined aortic atherosclerosis [55]. However, an updated analysis of the Copenhagen General Population Study suggests that the cholesterol content in VLDL, but not the TG content, is the main contributor to atherosclerotic disease [56].
Table 2 Multivariable adjusted change in cSBP by quartiles of blood lipids, considered individually

| Variable            | Change in cSBP, mmHg (95% CI) | P value |
|---------------------|--------------------------------|---------|
| TC, mmol/L          |                                 |         |
| Continuous, per 1 mmol/L | 1.20 (0.73–1.67) | < 0.001 |
| Quartiles           |                                 |         |
| Q1: < 4.70          | Ref.                            |         |
| Q2: 4.70–< 5.28     | 0.72 (−0.57–2.00) | 0.274   |
| Q3: 5.28–< 5.95     | 1.99 (0.71–3.28) | 0.002   |
| Q4: ≥5.95           | 2.58 (1.28–3.88) | < 0.001 |
| TG, mmol/L          |                                 |         |
| Continuous, per 1 mmol/L | 0.84 (0.49–1.19) | < 0.001 |
| Quartiles           |                                 |         |
| Q1: < 0.87          | Ref.                            |         |
| Q2: 0.87–< 1.24     | 1.51 (0.23–2.80) | 0.021   |
| Q3: 1.24–< 1.79     | 2.30 (0.98–3.61) | < 0.001 |
| Q4: ≥1.79           | 4.22 (2.87–5.57) | < 0.001 |
| HDL-C, mmol/L       |                                 |         |
| Continuous, per 1 mmol/L | −1.43 (−2.76–−0.10) | 0.035   |
| Quartiles           |                                 |         |
| Q1: < 1.19          | Ref.                            |         |
| Q2: 1.19–< 1.42     | −0.74 (−2.05–0.57) | 0.268   |
| Q3: 1.42–< 1.68     | −1.00 (−2.36–0.36) | 0.151   |
| Q4: ≥1.68           | −1.60 (−3.03–−0.17) | 0.028   |
| Non-HDL-C, mmol/L   |                                 |         |
| Continuous, per 1 mmol/L | 1.00 (0.44–1.56) | < 0.001 |
| Quartiles           |                                 |         |
| Q1: < 2.73          | Ref.                            |         |
| Q2: 2.73–< 3.24     | 1.40 (0.12–2.68) | 0.032   |
| Q3: 3.24–< 3.78     | 1.35 (0.06–2.64) | 0.041   |
| Q4: ≥3.78           | 2.63 (1.34–3.93) | < 0.001 |
| RLP-C, mmol/L       |                                 |         |
| Continuous, per 1 mmol/L | 1.38 (0.91–1.85) | < 0.001 |
| Quartiles           |                                 |         |
| Q1: < 3.22          | Ref.                            |         |
| Q2: 3.22–< 3.83     | 2.33 (1.05–3.60) | < 0.001 |
| Q3: 3.83–< 4.49     | 2.14 (0.85–3.43) | 0.001   |
| Q4: ≥4.49           | 3.88 (2.57–5.18) | < 0.001 |

Model adjusted for age, sex, body mass index, estimated glomerular filtration rate, smoking status, drinking status, diabetes mellitus, antidiabetic drug use, history of myocardial infarction and history of stroke

Abbreviations: TC total cholesterol, TG triglyceride, HDL-C high-density lipoprotein cholesterol, LDL-C low-density lipoprotein cholesterol, non-HDL-C non-high-density lipoprotein cholesterol, RLP-C remnant lipoprotein cholesterol, cSBP central systolic blood pressure

Some studies have focused on the influences of lipid-lowering agents on blood pressure. Statins could substantially reduce peripheral blood pressure (1 to 3 mmHg) [57, 58], improve arterial stiffness, and reduce central aortic pressure [59], despite the negative effects of atorvastatin on central hemodynamic parameters identified in the Conduit Artery Function Evaluation-Lipid-Lowering Arm study [60]. Considering the high comorbidity of hypertension and dyslipidemia possibly mediated by adiposity [61], the exact relationship between blood pressure and lipids should be investigated. A recent study showed that statin therapy could enhance blood pressure control in patients with hypertension, independently of the intensity of antihypertensive agents [62]. A mediation analysis also showed that LDL-C reduction after statin treatment is associated with better central blood pressure control [63]. The exact action of lipid-lowering agents on central blood pressure remains unknown, but clinicians should consider performing comprehensive measurement of central blood pressure and lipids profile in individuals with hypertension or dyslipidemia. To uncover the natural relationship of RLP-C with cSBP, participants taking lipid-lowering agents or antihypertensive medications were excluded in this study. Considering that these treated participants may have higher values of lipids or cSBP, analyses after including them were also performed, and the main findings were not substantially changed.

**Study strengths and limitations**

This study demonstrated the association between RLP-C and cSBP for the first time, which strengthens the association between blood lipid levels and vascular health from the viewpoint of cSBP. Among the analyzed lipid parameters, RLP-C showed the strongest association with cSBP, offering a novel research direction.

This study also has several limitations. First, central diastolic pressure and pulse pressure were not discussed because the Omron devices used in this study do not measure central diastolic pressure. Second, the enrolled participants were from one site; thus, generalizability of the findings to other populations is unclear. Third, other measures of central arterial stiffness, such as carotid-femoral PWV, were not available in this study. Fourth, despite finding no collinearity in the VIF calculations, the effects of RLP-C on cSBP might not be independent of other lipids because RLP-C has a linear relationship with other lipid fractions. Thus, routine lipid fraction tests and RLP-C assessment should be conducted simultaneously in both scientific research and clinical practice. Last, causality between RLP-C and cSBP cannot be judged because...
of the characteristics of a cross-sectional study; additional studies are warranted to determine whether a causal relationship exists between dyslipidemia and increased non-invasive cSBP or whether these are components of a single disease or pathological state, like metabolic syndrome.

Conclusions

Increased blood RLP-C level was significantly associated with higher cSBP in a Chinese community-based population, independently of other lipid levels. These findings emphasize the importance of RLP-C in comprehensive individual cardiovascular risk assessment. Further studies should focus on determining causality and potential mechanisms in this relationship.

Abbreviations
cSBP: Central systolic blood pressure; TRLs: Triglyceride-rich lipoproteins; TC: Total cholesterol; BMI: Body mass index; TG: Triglyceride; PWV: Pulse wave velocity; CAVI: Cardio-ankle vascular index; eGFR: Estimated glomerular filtration rate; IDL: Intermediate-density lipoprotein; VLDL: Very low-density lipoprotein
lipoprotein; HDL-C: High-density lipoprotein cholesterol; DM: Diabetes mellitus; PWA: Pulse wave analysis; LDL-C: Low-density lipoprotein cholesterol; RLP-C: Remnant lipoprotein cholesterol; non-HDL-C: non-high-density lipoprotein cholesterol; CI: confidence interval

Acknowledgments
We thank the entire study team for their participation and contributions. We also thank Kelly Zammit, BVSc, from Liwen Bianji (Edanz) (www.liwenbianji.cn/), for editing the English text of a draft of this manuscript.

Authors’ contributions
Y.Z. and J.Z. are responsible for the data resources and integrity. Y.Z., J.Z., B.Z. and Y.H. were in charge of the study concept and design. Y.Z., F.F., J.J., KL., BL., J.L. and C.C. conducted the entire study. F.F. and J.J. helped with data management and statistical analysis. K.L. analyzed the data and drafted the manuscript, and Y.Z., J.Z., Y.H., B.Z., F.F., J.J., BL., J.L. and C.C. reviewed and revised the article. The authors read and approved the final manuscript.

Funding
University of Michigan Health Science -Peking University Health Science Centre (UMHS-PHUSC) Joint Institute for translational and Clinical research and the Fundamental Research Funds for the Central Universities (Grant No: BMU201410177 and BMU20160530); National Key Research and Development Project of China (Grant No. 2017YFC1007074); Key Laboratory of Molecular Cardiovascular Sciences (Peking University), Ministry of Education and National Health Commission Key Laboratory of Cardiovascular Molecular Biology and Regulatory Peptides; Chinese Cardiovascular Association- Access fund 2019-CCA-ACCESS-112.

Availability of data and materials
Data are available with reasonable request.

Declarations

Ethics approval and consent to participate
The study protocol was approved by Peking University First Hospital Ethics Committee, and all participants provided written informed consent. The study was performed in accordance with the principles of the Declaration of Helsinki.

Consent for publication
Not applicable.

Competing interests
None.

Author details
1Department of Cardiology, Peking University First Hospital, No. 8 Xishiku Street, Xicheng District, Beijing 100034, China. 2Institute of Cardiovascular Disease, Peking University First hospital, No. 8 Xishiku Street, Xicheng District, Beijing 100034, China.

Received: 31 January 2021 Accepted: 14 June 2021
Published online: 26 June 2021

References
1. Poultier NR, Prabhakaran D, Caulfield M. Hypertension. Hypertension Lancet. 2015;386(9995):801–12. https://doi.org/10.1016/S0140-6736(14)61466-9.
2. Roth GA, Mensah GA, Johnson CO, Addolorato G, Ammirati E, Baddour LM, et al. Global burden of cardiovascular diseases and risk factors, 1990-2019: update from the GBD 2019 study. J Am Coll Cardiol. 2020;76(25):2982–2021. https://doi.org/10.1016/j.jacc.2020.11.010.
3. Cheng HM, Chuang SY, Wang TD, Kario K, Buranakitjaroen P, Chia YC, et al. Central blood pressure for the management of hypertension: is it a practical clinical tool in current practice? J Clin Hypertens (Greenwich). 2020;22(3):391–406. https://doi.org/10.1007/s12574-018-21023-7.
4. Vlachopoulos C, Ast远turis K, O’Rourke MF, Safar ME, Baou K, Stefanadis C. Prediction of cardiovascular events and all-cause mortality with central haemodynamics: a systematic review and meta-analysis. Eur Heart J. 2010; 31(15):1865–71. https://doi.org/10.1093/eurheartj/ehq024.
5. Wang KL, Cheng HM, Chuang SY, Spurgeon HA, Ting CT, Lakatta EG, et al. Central or peripheral systolic or pulse pressure: which best relates to target organs and future mortality? J Hypertens. 2009;27(3):461–7. https://doi.org/10.1097/HJH.0b013e32833320a4.
6. Chi C, Yu X, Auksle R, Lu Y, Fan X, Yu S, et al. Hypertensive target organ damage is better related with central than brachial blood pressure the northern Shanghai study. J Clin Hypertens (Greenwich). 2017;19(12):1269–75. https://doi.org/10.1111/jch.13110.
7. Kollas A, Lagou S, Zenioudi ME, Boubouchairoupolou N, Stergiou GS. Association of Central Versus Brachial Blood Pressure with Target-Organ Damage: systematic review and meta-analysis. Hypertension. 2016;67(1):183–90. https://doi.org/10.1161/HYPERTENSIONAHA.115.06666.
8. Wilkinson IB, Prasad K, Hall IR, Thomas A, MacCallum H, Webb DJ, et al. Increased central pulse pressure and augmentation index in subjects with hypercholesterolemia. J Am Coll Cardiol. 2002;39(6):1005–11. https://doi.org/10.1016/S0735-1097(01)7230-0.
9. Ferrara LA, Guida L, Iannuzzi R, Celetano A, Lionello F. Serum cholesterol affects blood pressure regulation. J Hum Hypertens. 2002;16(5):337–43. https://doi.org/10.1038/sj.jhh.1001388.
10. Mancia G, Facchetti R, Bombelli M, Polo Friz H, Gasii G, Giannattasio C, et al. Relationship of office, home, and ambulatory blood pressure to blood glucose and lipid variables in the PAMELA population. Hypertension. 2005; 45(6):1072–7. https://doi.org/10.1161/111091165769176.ed.
11. Yan Z, Bi-Rong D, Hui W, Chang-Quan H. Serum lipid/ lipoprotein and arterial blood pressure among Chinese nonagenarians/centenarians. Blood Press. 2011;20(5):296–302. https://doi.org/10.3109/08080979.2011.572590.
12. Castaner O, Pinto X, Subirana I, Amor AJ, Res E, Hemaee A, et al. Remnant cholesterol, not LDL cholesterol, is associated with incident cardiovascular disease. J Am Coll Cardiol. 2020;76(23):2712–24. https://doi.org/10.1016/j.jcc.2020.10.008.
13. Joshi PH, Khokhar AA, Massaro JM, Litteet ST, Griswold ME, Martin SS, et al. Remnant Lipoprotein Cholesterol and Incident Coronary Heart Disease: The Jackson Heart and Framingham Offspring Cohort Studies. J Am Heart Assoc. 2016;5(5). https://doi.org/10.1161/JAHA.115.002765.
14. Chapman MJ, Ginsberg HN, Amarenco P, Andreotti F, Boren J, Catapano AL, et al. Triglyceride-rich lipoproteins and high-density lipoprotein cholesterol in patients at high risk of cardiovascular disease: evidence and guidance for management. Eur Heart J. 2011;32(13):1345–61. https://doi.org/10.1093/eurheartj/ehr112.
15. Kasahara A, Adachi H, Hira H, Enomoto M, Fukami A, Yoshikawa K, et al. High level of plasma remnant-like particle cholesterol may predispose to development of hypertension in normotensive subjects. Am J Hypertens. 2013;26(6):793–8. https://doi.org/10.1016/j.ajh.2011.04.011.
16. Fan F, Qi L, Jia J, Xu X, Liu Y, Yang Y, et al. Noninvasive central systolic blood pressure is more strongly related to kidney function decline than peripheral systolic blood pressure in a Chinese community-based population. Hypertension. 2016;67(5):1166–72. https://doi.org/10.1161/HYPERTENSIONAHA.115.07019.
17. Morin M, Fan F, Li J, Qin X, Jia Q, Li Q, et al. Associations of plasma homocysteine levels with peripheral systolic blood pressure and noninvasive central systolic blood pressure in a community-based Chinese population. Sci Rep. 2017;7(1):8316. https://doi.org/10.1038/s41598-017-06611-3.
18. Fan F, Jia J, Li J, Huo Y, Zhang Y. White blood cell count predicts the odds of kidney function decline in a Chinese community-based population. BMC Nephrol. 2017;18(1):190. https://doi.org/10.1186/s12882-017-0608-4.
19. Wang S, Zhou Z, Fan F, Qi L, Jia J, Sun P, et al. Joint effect of non-invasive central systolic blood pressure and peripheral systolic blood pressure on incident hypertension in a Chinese community-based population. Sci Rep. 2018;8(1):3229. https://doi.org/10.1038/s41598-018-21023-7.
20. Takazawa K, Kobayashi H, Kojima I, Asaka A, Kinosh M, Sugo Y, et al. Estimation of central aortic systolic pressure using late systolic inflection of radial artery pulse and its application to vasodilator therapy. J Hypertens. 2012;30(5):908–16. https://doi.org/10.1097/HJH.0b013e3283524910.
21. Takazawa K, Kobayashi H, Shindo N, Tanaka N, Yamashita A. Relationship between radial and central arterial pulse wave and evaluation of central aortic pressure using the radial arterial pulse wave. Hypertens Res. 2007; 30(3):219–28. https://doi.org/10.1038/ajh.2011.145.
Zhan B, Huang X, Wang J, Qin X, Zhang J, Cao J, et al. Association between arterial stiffness assessed by cardioankle vascular index and brachial-ankle pulse wave velocity in a Nationwide population-based sample: Kardiovize Brno 2030 study. Lipids Health Dis. 2019;18(1):212. https://doi.org/10.1186/s12944-018-0881-y.

Adank MC, Benschop L, Peterbroers KR, Smak Gregoor AM, Kors AW, Mulder MT, et al. Is maternal lipid profile in early pregnancy associated with pregnancy complications and blood pressure in pregnancy and long term postpartum? Am J Obstet Gynecol. 2019;221(2):150 e1-e13.

Stancu CS, Toma L, Sima AV. Dual role of lipoproteins in endothelial cell dysfunction in arteriosclerosis. Cell Tissue Res. 2012;349(2):433–46. https://doi.org/10.1007/s00441-012-1437-1.

Zheng XY, Liu L. Remnant-like lipoprotein particles impair endothelial vasomotor function induced by the combination of hypertension and hypercholesterolemia. J Am Soc Hypertens. 2013;7(1):141–148. https://doi.org/10.1161/01.CIR.102.6.670.

Boghi C, Uro R, Ciceri AF. Renin-angiotensin system at the crossroad of hypertension and hypercholesterolemia. Nutr Metab Cardiovasc Dis. 2017;27(2):115–20. https://doi.org/10.1016/j.numecrd.2016.07.013.

Kurtel H, Rodrigues SF, Yilmaz CE, Yildirim A, Granger DN. Impaired vasomotor function induced by the combination of hypertension and hypercholesterolemia. J Am Soc Hypertens. 2013;7(1):14–23. https://doi.org/10.1016/j.jash.2012.11.005.

Sposito AC. Emerging insights into hypertension and dyslipidaemia synergies. Eur Heart J Suppl. 2004;6(7):G8–12. https://doi.org/10.1016/j.ehjsup.2004.10.003.

Ivanovíc B, Tadic M. Hypercholesterolemia and hypertension: two sides of the same coin. Am J Cardiovasc Drugs. 2015;15(6):403–14. https://doi.org/10.1007/s10459-015-9364-0.

Kabutoya T, Kario K. Comparative assessment of cutoffs for the carotid-ankle vascular index and brachial-ankle pulse wave velocity in a Nationwide registry: a cardiovascular prognostic coupling study. Pulse (Basel). 2019;6(3–4):131–6. https://doi.org/10.1016/j.jash.2019.03.034.

Salvi P, Scalise F, Rovina M, Moretti F, Salvi L, Grillo A, et al. Noninvasive estimation of aortic stiffness through different approaches. Hypertension. 2019;73(3):477–484. https://doi.org/10.1161/HYPERTENSIONAHA.118.12851.

Namba T, Masaki N, Takase B, Adachi T. Arterial Stiffness Assessed by Cardioankle Vascular Index. Int J Mol Sci. 2019;20(15). https://doi.org/10.3390/ijms20156700.

Pavlovska I, Kunzova S, Jakubkova J, Hruskova J, Skladana M, Rivas-Serna IM, et al. Comparison of central pressure estimates obtained from SphygmCor, Omron HEM-9000AI and carotid applanation tonometry. J Hypertens. 2011;29(6):1115–20. https://doi.org/10.1097/HJH.0b013e32834e683c.

Yeom H, Kim HC, Lee JM, Jeon Y, Shin I. Triglyceride to high density lipoprotein cholesterol ratio among adolescents is associated with adult hypertension: the Kangwondo study. Lipids Health Dis. 2018;17(1):212. https://doi.org/10.1186/s12944-018-0881-y.

Sposito AC. Emerging insights into hypertension and dyslipidaemia synergies. Eur Heart J Suppl. 2004;6(7):G8–12. https://doi.org/10.1016/j.ehjsup.2004.10.003.

Ivanovic B, Tadic M. Hypercholesterolemia and hypertension: two sides of the same coin. Am J Cardiovasc Drugs. 2015;15(6):403–14. https://doi.org/10.1007/s10459-015-9364-0.

Kabutoya T, Kario K. Comparative assessment of cutoffs for the carotid-ankle vascular index and brachial-ankle pulse wave velocity in a Nationwide registry: a cardiovascular prognostic coupling study. Pulse (Basel). 2019;6(3–4):131–6. https://doi.org/10.1016/j.jash.2019.03.034.

Salvi P, Scalise F, Rovina M, Moretti F, Salvi L, Grillo A, et al. Noninvasive estimation of aortic stiffness through different approaches. Hypertension. 2019;73(3):477–484. https://doi.org/10.1161/HYPERTENSIONAHA.118.12851.

Namba T, Masaki N, Takase B, Adachi T. Arterial Stiffness Assessed by Cardioankle Vascular Index. Int J Mol Sci. 2019;20(15). https://doi.org/10.3390/ijms20156700.

Pavlovska I, Kunzova S, Jakubkova J, Hruskova J, Skladana M, Rivas-Serna IM, et al. Comparison of central pressure estimates obtained from SphygmCor, Omron HEM-9000AI and carotid applanation tonometry. J Hypertens. 2011;29(6):1115–20. https://doi.org/10.1097/HJH.0b013e32834e683c.

Yeom H, Kim HC, Lee JM, Jeon Y, Shin I. Triglyceride to high density lipoprotein cholesterol ratio among adolescents is associated with adult hypertension: the Kangwondo study. Lipids Health Dis. 2018;17(1):212. https://doi.org/10.1186/s12944-018-0881-y.

Sposito AC. Emerging insights into hypertension and dyslipidaemia synergies. Eur Heart J Suppl. 2004;6(7):G8–12. https://doi.org/10.1016/j.ehjsup.2004.10.003.

Ivanovic B, Tadic M. Hypercholesterolemia and hypertension: two sides of the same coin. Am J Cardiovasc Drugs. 2015;15(6):403–14. https://doi.org/10.1007/s10459-015-9364-0.

Kabutoya T, Kario K. Comparative assessment of cutoffs for the carotid-ankle vascular index and brachial-ankle pulse wave velocity in a Nationwide registry: a cardiovascular prognostic coupling study. Pulse (Basel). 2019;6(3–4):131–6. https://doi.org/10.1016/j.jash.2019.03.034.

Salvi P, Scalise F, Rovina M, Moretti F, Salvi L, Grillo A, et al. Noninvasive estimation of aortic stiffness through different approaches. Hypertension. 2019;73(3):477–484. https://doi.org/10.1161/HYPERTENSIONAHA.118.12851.

Namba T, Masaki N, Takase B, Adachi T. Arterial Stiffness Assessed by Cardioankle Vascular Index. Int J Mol Sci. 2019;20(15). https://doi.org/10.3390/ijms20156700.

Pavlovska I, Kunzova S, Jakubkova J, Hruskova J, Skladana M, Rivas-Serna IM, et al. Comparison of central pressure estimates obtained from SphygmCor, Omron HEM-9000AI and carotid applanation tonometry. J Hypertens. 2011;29(6):1115–20. https://doi.org/10.1097/HJH.0b013e32834e683c.

Yeom H, Kim HC, Lee JM, Jeon Y, Shin I. Triglyceride to high density lipoprotein cholesterol ratio among adolescents is associated with adult hypertension: the Kangwondo study. Lipids Health Dis. 2018;17(1):212. https://doi.org/10.1186/s12944-018-0881-y.
61. Spannella F, Giulietti F, Di Pentima C, Sarzani R. Prevalence and control of dyslipidemia in patients referred for high blood pressure: the disregarded "double-trouble" lipid profile in overweight/obese. Adv Ther. 2019;36(6):1426–37. https://doi.org/10.1007/s12325-019-00941-6.

62. Spannella F, Filipponi A, Giulietti F, Di Pentima C, Bordoni V, Sarzani R. Statin therapy is associated with better ambulatory blood pressure control: a propensity score analysis. J Hypertens. 2020;38(3):546–52. https://doi.org/10.1097/HJH.0000000000002276.

63. Lamarche F, Agharazii M, Nadeau-Fredette AC, Madore F, Goupil R. Central and brachial blood pressures, statins, and low-density lipoprotein cholesterol: a mediation analysis. Hypertension. 2018;71(3):415–21. https://doi.org/10.1161/HYPERTENSIONAHA.117.10476.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.